The latest price target for Aileron Therapeutics (NASDAQ:ALRN) was reported by Ladenburg Thalmann on April 18, 2024. The analyst firm set a price target for $19.00 expecting ALRN to rise to within 12 months (a possible 636.43% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Aileron Therapeutics (NASDAQ:ALRN) was provided by Ladenburg Thalmann, and Aileron Therapeutics maintained their buy rating.

The last upgrade for Aileron Therapeutics Inc happened on December 1, 2023 when Ladenburg Thalmann raised their price target to $9. Ladenburg Thalmann previously had a neutral for Aileron Therapeutics Inc.

The last downgrade for Aileron Therapeutics Inc happened on June 29, 2022 when William Blair changed their price target from N/A to N/A for Aileron Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aileron Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aileron Therapeutics was filed on April 18, 2024 so you should expect the next rating to be made available sometime around April 18, 2025.

While ratings are subjective and will change, the latest Aileron Therapeutics (ALRN) rating was a maintained with a price target of $9.00 to $19.00. The current price Aileron Therapeutics (ALRN) is trading at is $2.58, which is out of the analyst’s predicted range.